


Summary

















In one aspect, there is provided a compound of formula (I)



including any stereochemically isomeric form thereof, wherein


X is N or CR⁶ wherein R⁶ is hydrogen, halo or C₁₋₄alkyl;

R¹ is CH₃ or CH₂CH₃, and R^{1'} is hydrogen; or R¹ and R^{1'} are taken together with the carbon atom to which they are attached to form cyclopropyl; and R² is C₃₋₆alkyl and R³ is C₁₋₄alkyl;

























Claims

1. A compound of formula (I)




- 5 including any stereochemically isomeric form thereof, wherein
X is N or CR⁶ wherein R⁶ is hydrogen, halo or C₁₋₄alkyl;
R¹ is CH₃ or CH₂CH₃, and R^{1'} is hydrogen; or R¹ and R^{1'} are taken together with the carbon atom to which they are attached to form cyclopropyl; and R² is C₃₋₆alkyl and R³ is C₁₋₄alkyl;

- 10 or the moiety is a radical of formula :



12. The compound according to claim 1 wherein the compound is



or a pharmaceutically acceptable salt thereof.

13. The compound as claimed in claim 12 wherein said compound has the (+) specific rotation measured in DMF as solvent.

14. The compound as claimed in claim 13 wherein said compound has a specific optical rotation of $[\alpha]_D^{20} = +156,37^\circ$ at a concentration of 0,259 (w/v%).

15. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically active amount of a compound as claimed in any of claims 1 to 14.

16. The pharmaceutical composition according to claim 15, which further comprises another antiviral agent.

17. The pharmaceutical composition according to claim 16, wherein the other antiviral agent is a RSV inhibiting compound.

18. The pharmaceutical composition according to claim 16 wherein the other antiviral agent is a RSV fusion inhibitor or a RSV polymerase inhibitor.

19. A process for preparing a pharmaceutical composition as claimed in any one of claims 15 to 18 wherein a therapeutically active amount of a compound as claimed in any of claims 1 to 14 is intimately mixed with a pharmaceutically acceptable carrier.

20. A compound as claimed in any of claims 1 to 14 for use as a medicine.

21. A compound as claimed in any of claims 1 to 14, or a pharmaceutical composition as claimed in any one of claims 15 to 18, for use in the treatment of a respiratory syncytial virus infection.

5 22. Use of a compound of formula (I) as defined in any one of claims 1 to 11 in the manufacture of a medicament for the treatment of a respiratory syncytial virus (RSV) infection.